s potential in the market. A key element is the company’s promising drug, denifanstat, a fatty acid synthase inhibitor, which has shown strong efficacy in Phase 2b trials, particularly among more ...

Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...

The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data ...

New study reports protective effect among people with type 2 diabetes Kidney stones and the systemic conditions associated with them have a major impact on health and the economy in the US and ...

Checkpoint inhibitors are a groundbreaking class of cancer treatment, but they come with two frustrating challenges. In some cases, tumors show no initial response, rendering the therapy ...

The global proton pump inhibitors (PPIs) market is currently valued at approximately USD 2.8 billion and is projected to grow ...

The study is evaluating AJ1-11095, a novel agent for the treatment of myelofibrosis that did not respond to or relapsed ...

Developed by Ascentage Pharma, lisaftoclax is a novel orally available Bcl-2 inhibitor with clinical benefits for an array of hematologic malignancies and solid tumors. At this year's ASH Annual ...

STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, ...

Patients with sarcoidosis treated with ACE inhibitors had greater mortality risk than those treated with angiotensin receptor blockers.